mAbxience

[ES] Este domingo, volvimos a llenar las calles de Madrid en la XII Carrera Madrid en Marcha Contra el Cáncer, uniéndonos a miles de corredores en apoyo a esta gran causa. Creemos en un mundo donde los medicamentos de alta calidad sean accesibles para todos, y participar en eventos como este refleja nuestro compromiso con la comunidad y la salud. Gracias a la Asociación Española contra el Cáncer por una organización impecable y, sobre todo, a nuestro equipo por demostrar, una vez más, que juntos podemos marcar la diferencia. #mAbxience #CarreraContraElCancer #Salud #Comunidad #MedicamentosAccesibles #withinmAbxience [EN] This Sunday, we took to the streets of Madrid once again for the XII Race Against Cancer, joining thousands of runners in support of this important cause. We believe in a world where high-quality medicines are accessible to all, and participating in events like this reflects our commitment to community and health. Thank you to Asociación Española contra el Cáncer for an impeccably organized event, and especially to our team for showing that, together, we can make a difference. #mAbxience #RaceAgainstCancer #Health #Community #AccessibleMedicines #withinmAbxience

🗞️ Expert insights, key events to look forward to, the latest industry and mAbxience news and employee highlights: don’t miss out and subscribe to our monthly newsletter for a quick and easy update directly in your LinkedIn notifications, keeping you informed on all things mAbxience and beyond! #BiopharmaNewsletter #withinmAbxience #mAbxienceBiopharmaInsights #BiopharmaNews

Biosimilars today: challenges or opportunities?🌍Biosimilars hold the key to expanding patient access and reducing healthcare costs, yet nearly 55% of products losing patent protection in the next decade may face no biosimilar competition. Why? In our latest blog, we break down the regulatory milestones, evolving market dynamics, and what must change to drive stronger biosimilar adoption. 🔗 Read more: https://lnkd.in/du5fA92q #BiopharmaTrends #Healthcare #Biosimilars #GlobalMarkets #mAbxience #BiopharmaRegulations

The evolution of cancer treatment is clear: the future lies in combination therapies that target multiple pathways simultaneously. At the Biosimilar Medicines Conference (#BIOS25) in Amsterdam, our Chief Medical Officer, Susana Millan, will join a panel of industry and clinical experts on April 4 at 11:30 AM to discuss how biosimilar repurposing and combination therapies can reshape treatment accessibility and improve patient outcomes. Don’t miss this insightful discussion with leading voices in the field. 📅 "Turning potential into action" 🕦 April 4 | 11:30 AM 📍 Biosimilar Medicines Conference, Amsterdam: https://lnkd.in/d87CrVn6 Will you be at #BIOS25? Let’s connect! #Biosimilars #Oncology #HealthcareInnovation #Biopharma #MedicinesForEurope Medicines for Europe

We’re heading to Amsterdam for #BIOS25! Next week, mAbxience will join the Biosimilar Medicines Conference (3-4 April 2025), organized by Medicines for Europe, where industry leaders, policymakers, regulators, and healthcare professionals come together to shape the future of biosimilars and patient access. 🌍 With biosimilars at a turning point, this is a key moment to discuss how policy, innovation, and collaboration can drive wider adoption and sustainable healthcare. 💡 Plus, stay tuned—we have an important panel discussion on day 2, featuring one of our team members! More details coming soon. 📍 Will you be there? Let’s connect in Amsterdam!  #Biosimilars #Biopharma #HealthcarePolicy #MedicinesForEurope

What is the biggest challenge in biosimilar adoption? #Biosimilars are safe, effective, and backed by strong regulatory frameworks. Still, studies reveal a surprising gap in awareness, slowing adoption and limiting patient access to cost-effective treatments. 💬 In our latest blog, Eduardo Cioppi, Global Commercial Director at mAbxience, dives into the key barriers and how education and market strategies can accelerate biosimilar uptake. 🔗 Read more: https://lnkd.in/d4snrRY7 #Biopharma #mAbxience #BiosimilarDevelopment #TreatmentAccessibility

📉Last month, we asked our community about the biggest hurdles in biosimilar adoption—51% pointed to regulatory barriers. Now, let’s look ahead! We’ll be diving deeper into this topic with our Global Commercial Director, Eduardo Cioppi, an expert in biosimilar market developments. Vote now and share your thoughts in the comments! #Biosimilars #Biopharma #mAbxience

En mAbxience, no solo ofrecemos empleos, sino carreras con impacto. Somos una empresa biofarmacéutica en crecimiento y buscamos nuevos talentos. 🌍 📍 Oportunidades en España (León & Madrid) y Argentina (Buenos Aires & Garín). ¡Es tu momento! Descubre nuestras vacantes y postúlate hoy. 🔗 https://lnkd.in/d3KCA77c #Empleo #mAbxience #Biotecnología #InnovaciónConImpacto [ENG] At mAbxience, we don’t just offer jobs—we offer careers with impact. As a growing biopharmaceutical company, we’re looking for talented professionals to join us! 🌍 📍 Opportunities in Spain (León & Madrid) & Argentina (Buenos Aires & Garín). Ready for your next challenge? Explore our latest openings & apply today! 🔗 https://lnkd.in/d3KCA77c #Hiring #mAbxience #BiotechCareers #InnovationWithImpact

Nos enorgullece contar con profesionales como Laura Rodríguez Álvarez, cuyo talento y liderazgo reflejan el gran potencial que se forma en León. Su historia es una inspiración y un ejemplo de cómo el esfuerzo y la formación abren puertas a grandes oportunidades. 🎬 No te pierdas su testimonio ⬇️ #TalentoLocal #OrgulloAlumni #SomosUnileon #Biopharma #Liderazgo [ENG] We are proud to have professionals like Laura Rodríguez Álvarez, whose talent and leadership showcase the incredible potential emerging from León. Her story is an inspiration and a reminder that hard work and education open doors to great opportunities. 🎬 Don’t miss her testimony ⬇️ #LocalTalent #ProudAlumni #WeAreUnileon #Biopharma #Leadership

[ESP] "En aquel momento éramos solo 15 trabajadores y ahora somos más de 500." En una entrevista con Radio León – Hoy por Hoy, nuestro director de planta, Luis Eduardo Fontanetti Alves da Silva, habla sobre la evolución de mAbxience, el papel de León como polo farmacéutico en España y nuestra apuesta por el talento local. Más del 55% de nuestra plantilla es de León, y muchos otros han elegido esta ciudad para desarrollar su carrera con nosotros. "Desde el principio, nuestra misión era clara: llevar medicamentos biológicos de alta calidad al mayor número posible de personas y pacientes en todo el mundo. Hoy, la empresa ha crecido, ha consolidado su pipeline y estamos en etapa comercial, produciendo más de 100 lotes de medicamentos al año (unos 500 kg de anticuerpos monoclonales), lo que equivale a más de 1.5 millones de dosis anuales." Con una historia de crecimiento, proyectos innovadores y una mirada puesta en el futuro, mAbxience sigue consolidándose como un referente en la industria biofarmacéutica. 📢 Escucha la entrevista completa aquí: https://lnkd.in/d3AZq4J8 #mAbxience #Crecimiento #Biopharma #IndustriaFarmacéutica #TalentoLocal #León #I+D #Biotecnología [ENG] "Back then, we were only 15 employees, and now we are more than 500." In an interview with Radio León – Hoy por Hoy, our plant director, Luis Eduardo Fontanetti Alves da Silva, discusses mAbxience’s evolution, León’s role as a key pharmaceutical hub in Spain, and our strong commitment to local talent. Over 55% of our workforce comes from León, while many others have chosen this city to develop their careers with us. "From the very beginning, our mission was clear: to bring high-quality biologic medicines to as many people and patients as possible. Today, the company has grown, solidified its pipeline, and entered the commercial stage, producing more than 100 batches of medicines per year (around 500 kg of monoclonal antibodies), amounting to over 1.5 million doses annually." With a journey of growth, groundbreaking projects, and a vision for the future, mAbxience continues to establish itself as a leader in the biopharmaceutical industry. 📢 Listen to the full interview here: https://lnkd.in/d3AZq4J8 #mAbxience #Growth #Biopharma #PharmaIndustry #LocalTalent #León #Innovation #Biotechnology